These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9427342)

  • 1. Alpha-helical CRF(9-41) prevents anxiogenic-like effect of NPY Y1 receptor antagonist BIBP3226 in rats.
    Kask A; Rägo L; Harro J
    Neuroreport; 1997 Nov; 8(16):3645-7. PubMed ID: 9427342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anxiogenic-like effect of the NPY Y1 receptor antagonist BIBP3226 administered into the dorsal periaqueductal gray matter in rats.
    Kask A; Rägo L; Harro J
    Regul Pept; 1998 Sep; 75-76():255-62. PubMed ID: 9802417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anxiogenic effect of corticotropin-releasing hormone in the dorsal periaqueductal grey.
    Martins AP; Marras RA; Guimarães FS
    Neuroreport; 1997 Nov; 8(16):3601-4. PubMed ID: 9427334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anxiogenic-like effect of the neuropeptide Y Y1 receptor antagonist BIBP3226: antagonism with diazepam.
    Kask A; Rägo L; Harro J
    Eur J Pharmacol; 1996 Dec; 317(2-3):R3-4. PubMed ID: 8997632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of CRF but not NPY in the anxiety regulation via NMDA receptors.
    Wierońska JM; Szewczyk B; Pałucha A; Brański P; Smiałowska M
    Pol J Pharmacol; 2003; 55(6):1119-24. PubMed ID: 14730109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropeptide Y blocks anxiogenic-like behavioral action of corticotropin-releasing factor in an operant conflict test and elevated plus maze.
    Britton KT; Akwa Y; Spina MG; Koob GF
    Peptides; 2000 Jan; 21(1):37-44. PubMed ID: 10704717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for involvement of neuropeptide Y receptors in the regulation of food intake: studies with Y1-selective antagonist BIBP3226.
    Kask A; Rägo L; Harro J
    Br J Pharmacol; 1998 Aug; 124(7):1507-15. PubMed ID: 9723965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropeptide Y Y1 receptor antagonist BIBP3226 produces conditioned place aversion in rats.
    Kask A; Kivastik T; Rägo L; Harro J
    Prog Neuropsychopharmacol Biol Psychiatry; 1999 May; 23(4):705-11. PubMed ID: 10390728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracerebroventricular injection of a neuropeptide Y-Y1 receptor agonist increases while BIBP3226, a Y1 antagonist, reduces the infarct volume following transient middle cerebral artery occlusion in rats.
    Chen SH; Cheung RT
    Neuroscience; 2003; 116(1):119-26. PubMed ID: 12535945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral effects of central administration of the novel CRF antagonist astressin in rats.
    Spina MG; Basso AM; Zorrilla EP; Heyser CJ; Rivier J; Vale W; Merlo-Pich E; Koob GF
    Neuropsychopharmacology; 2000 Mar; 22(3):230-9. PubMed ID: 10693150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential roles of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence.
    Lu L; Liu D; Ceng X; Ma L
    Eur J Neurosci; 2000 Dec; 12(12):4398-404. PubMed ID: 11122350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corticotropin-releasing factor antagonist attenuates the "anxiogenic-like" effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats.
    Basso AM; Spina M; Rivier J; Vale W; Koob GF
    Psychopharmacology (Berl); 1999 Jul; 145(1):21-30. PubMed ID: 10445369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior.
    Stenzel-Poore MP; Heinrichs SC; Rivest S; Koob GF; Vale WW
    J Neurosci; 1994 May; 14(5 Pt 1):2579-84. PubMed ID: 8182429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo inhibition of neuropeptide FF agonism by BIBP3226, an NPY Y1 receptor antagonist.
    Fang Q; Guo J; He F; Peng YL; Chang M; Wang R
    Peptides; 2006 Sep; 27(9):2207-13. PubMed ID: 16762456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropeptide Y Y1 receptor-mediated anxiolysis in the dorsocaudal lateral septum: functional antagonism of corticotropin-releasing hormone-induced anxiety.
    Kask A; Nguyen HP; Pabst R; Von Hörsten S
    Neuroscience; 2001; 104(3):799-806. PubMed ID: 11440811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orexigenic effect of the melanocortin MC4 receptor antagonist HS014 is inhibited only partially by neuropeptide Y Y1 receptor selective antagonists.
    Kask A; Schiöth HB; Harro J; Wikberg JE; Rägo L
    Can J Physiol Pharmacol; 2000 Feb; 78(2):143-9. PubMed ID: 10737677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anxiolytic effect of a CRH receptor antagonist in the dorsal periaqueductal gray.
    Martins AP; Marras RA; Guimarães FS
    Depress Anxiety; 2000; 12(2):99-101. PubMed ID: 11091933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The blockage of ventromedial hypothalamus CRF type 2 receptors impairs escape responses in the elevated T-maze.
    Silva MSCF; Souza TMO; Pereira BA; Ribeiro DA; Céspedes IC; Bittencourt JC; Viana MB
    Behav Brain Res; 2017 Jun; 329():41-50. PubMed ID: 28435125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulation of neurons in rat ARC inhibits gastric acid secretion via hypothalamic CRF1/2- and NPY-Y1 receptors.
    Tebbe JJ; Mronga S; Schäfer MK; Rüter J; Kobelt P; Mönnikes H
    Am J Physiol Gastrointest Liver Physiol; 2003 Dec; 285(6):G1075-83. PubMed ID: 12855401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NPY Y1 receptors in the dorsal periaqueductal gray matter regulate anxiety in the social interaction test.
    Kask A; Rägo L; Harro J
    Neuroreport; 1998 Aug; 9(12):2713-6. PubMed ID: 9760107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.